Blockade of αvβ6 integrin represents an attractive anti-fibrotic drug mechanism, with a body of evidence to suggest that it plays a central role in the activation of TGFβ and the pathogenesis of lung fibrosis [16]. The gene discussed is TGFB1; the disease is pulmonary fibrosis.